R. Parisi, D. Symmons, C. Griffiths, and D. Ashcroft, Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence, Journal of Investigative Dermatology, vol.133, issue.2, pp.377-85, 2013.
DOI : 10.1038/jid.2012.339

A. Nast, P. Gisondi, A. Ormerod, P. Saiag, C. Smith et al., European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC, Journal of the European Academy of Dermatology and Venereology, vol.66, issue.12, pp.2277-94, 2015.
DOI : 10.1016/j.jclinepi.2012.03.013

P. Spuls, L. Lecluse, M. Poulsen, J. Bos, R. Stern et al., How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review, Journal of Investigative Dermatology, vol.130, issue.4, pp.933-976, 2010.
DOI : 10.1038/jid.2009.391

S. Fenix-caballero, A. Rey, E. Castano-lara, R. Puigventos-latorre, F. Borrero-rubio et al., Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis, Journal of Clinical Pharmacy and Therapeutics, vol.129, issue.Suppl 3, pp.286-93, 2013.
DOI : 10.1157/13113299

G. Burmester, R. Panaccione, K. Gordon, M. Mcilraith, and A. Lacerda, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease, Annals of the Rheumatic Diseases, vol.72, issue.4
DOI : 10.1136/annrheumdis-2011-201244

A. Nast, B. Sporbeck, S. Rosumeck, D. Pathirana, A. Jacobs et al., Which Antipsoriatic Drug Has the Fastest Onset of Action????Systematic Review on the Rapidity of the Onset of Action, Journal of Investigative Dermatology, vol.133, issue.8, pp.1963-70, 2013.
DOI : 10.1038/jid.2013.78

J. Keane, G. S. Wise, R. Mirabile-levens, E. Kasznica, J. Schwieterman et al., Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor ?????Neutralizing Agent, New England Journal of Medicine, vol.345, issue.15, pp.1098-104, 2001.
DOI : 10.1056/NEJMoa011110

F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille et al., Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry, Arthritis & Rheumatism, vol.18, issue.7, pp.1884-94, 2009.
DOI : 10.4049/jimmunol.168.7.3394
URL : https://hal.archives-ouvertes.fr/inserm-00400633

T. Tsai, H. Chiu, M. Song, and D. Chan, A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial, British Journal of Dermatology, vol.3, issue.2, pp.444-450, 2013.
DOI : 10.4161/mabs.3.6.17815

T. Tsai, V. Ho, M. Song, P. Szapary, T. Kato et al., The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection, British Journal of Dermatology, vol.167, issue.5, pp.1145-52, 2012.
DOI : 10.1164/rccm.200206-626OC

E. Guinard, B. Livideanu, C. Barthelemy, H. Viguier, M. Reguiai et al., Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study, Journal of the European Academy of Dermatology and Venereology, vol.54, issue.Suppl 4, pp.1336-1377, 2016.
DOI : 10.1111/ijd.12628

Y. Abitbol, D. Laharie, J. Cosnes, M. Allez, S. Nancey et al., Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort, Journal of Crohn's and Colitis, vol.24, issue.10, pp.1179-85, 2016.
DOI : 10.1056/NEJMoa1215734
URL : https://hal.archives-ouvertes.fr/hal-01470713

R. Gniadecki, K. Kragballe, T. Dam, and L. Skov, Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. The British journal of dermatology, pp.1091-1097, 2011.

F. Cantini, L. Niccoli, C. Nannini, E. Cassara, O. Kaloudi et al., Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis, Seminars in Arthritis and Rheumatism, vol.45, issue.5, pp.519-551, 2016.
DOI : 10.1016/j.semarthrit.2015.10.001